

Partner, Brussels

Antitrust/Competition



T: 32.2.639.0337
rafique.bachour@skadden.com

Education

Legal Practice Course, College of Law,
London, 1999

Postgraduate Diploma in EU
Competition Law, King's College
London, 1998

LL.M, University of London, 1997

LL.B, University of Damascus, Syria,
1996

Bar Admissions

Brussels

England & Wales

Ireland

Languages

English

Arabic

French

Rafique Bachour has more than 25 years of experience in EU, U.K. and international competition law. He focuses his practice on antitrust and regulatory aspects of global M&A transactions, cartels, international antitrust investigations and a variety of other matters.

Mr. Bachour has extensive experience managing large-scale transactions that require global regulatory and merger-control strategies. He has advised clients across a range of sectors, including oil and gas, chemicals and petrochemicals, mining, aviation and electronics, among others. He also regularly counsels global financial investors, sovereign wealth funds and pension funds on investments and compliance matters.

Mr. Bachour also regularly counsels on antitrust compliance and investigations, having defended clients in antitrust investigations focused on automotive products, computer components, semiconductors and renewable fuels, among other areas.

In recognition of his work, Mr. Bachour has been ranked as a leader in his field in *Chambers Global* and *Chambers Europe*, as well as honored by *Lexology Index: Competition* as a Global Elite Thought Leader. He also lectures at King's College London, where he teaches a course on competition law.

Prior to joining Skadden, Mr. Bachour's transactional representations included advising:

- Teck Resources on its \$53 billion merger with Anglo American
- ADNOC on its \$16.4 billion successful bid to acquire Covestro AG
- Suzano on its \$3.4 billion global joint venture with Kimberly-Clark
- UBS on its \$3.25 billion acquisition of Credit Suisse
- Ericsson on its \$6.2 billion acquisition of Vonage
- AstraZeneca on its:
 - \$39 billion acquisition of Alexion Pharmaceuticals
 - \$8 billion strategic oncology collaboration with Merck
- BASF on its €7.6 billion acquisition of significant components of Bayer's seed and crop protection businesses and related assets
- Suzano Papel e Celulose, a Brazilian paper and pulp manufacturer, on its \$11 billion acquisition of Fibria Celulose
- Johnson & Johnson on its \$30 billion public takeover of Actelion
- Holcim on its \$43 billion merger of equals with Lafarge